With a new sales management team and now a new group purchasing agreement, the orthobiologics company Cerapedics, Inc. is on the move! The company has just been awarded an agreement with Premier Inc., a leading healthcare improvement company, for Breakthrough Technology: Bone Tissue Synthetic Implantable Products. Premier members will have the option of special pricing and terms pre-negotiated by Premier for i-FACTOR Peptide Enhanced Bone Graft.
Cerapedics: Group Purchasing Agreement With Premier
1 min read Premium comments
Secondary
“We are pleased to announce our new agreement with Premier because it will help us provide a growing number of surgeons with the advanced biologic they need to stimulate a natural bone healing process in patients with degenerative cervical disc disease, ” said Cerapedics CEO Glen Kashuba. “We look forward to the continued expansion of i-FACTOR Bone Graft commercialization into the new year.”
According to the November 30, 2016 news release, “i-FACTOR Bone Graft is based on synthetic small peptide (P-15) technology developed by Cerapedics to support bone growth through cell attachment and activation. Supported by Level I human clinical data, i-FACTOR Bone Graft received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) in November 2015.”
“Premier unites an alliance of approximately 3, 750 U.S. hospitals and 130, 000 other provider organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.”
Glen Kashuba told OTW, “After educating Premier about our technology, we were invited to submit i-FACTOR through their special Breakthrough Technology review process. On the Orthopedic Committee’s recommendation, we were awarded the contract outside of their standard Osteobiologics contracting review cycle.”
Asked for details on the expansion of i-FACTOR Bone Graft commercialization, he noted, “Early commercialization is going well with exceptional interest in both the spine surgeon and distributor communities. We recently completed an expansion of the sales management team to develop stronger distributor networks and to drive growth.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.